Charlotte, NC, October 8, 2020 – Bundy Group, a healthcare and life sciences-focused investment bank focused on the advisory needs of clients for over 31 years, is pleased to announce that Catawba Research has partnered with a financial investment firm focused on control investments in the life sciences sector. Catawba Research is a premier international, full-service contract research organization (“CRO”) that provides clinical management services to pharmaceutical and biotechnology companies. The investment will support Catawba Research’s next phase of growth and strengthen its position within the life sciences market.
This transaction represents the first institutional capital placed into Catawba Research. The new partnership will serve as an important milestone in Catawba Research’s goal of becoming a leading international pharmaceutical services organization. Following the acquisition, Zaidoon A. Al-Zubaidy, Founder and Chief Executive Officer, and the existing senior management team will continue to operate Catawba Research while the new financial partner will offer additional resources and board-level support.
Zaidoon A. Al-Zubaidy commented, “Catawba Research is excited to take this journey with our partners who share our ‘people first’ values. This is an exciting time for our team and our loyal sponsors. With this partnership, we are confident that Catawba will become one of the premier global clinical research providers.”
“Catawba Research has built an outstanding foundation of talent and operational excellence,” commented Stewart Carlin, Director with Bundy Group. “The company has continually demonstrated its ability to form lasting relationships with pharmaceutical sponsors and deliver superior results through consistent innovation and vertical integration. We are thrilled to have advised on this transaction, and we believe this new partnership will allow Catawba Research to accelerate its growth and value creation in the future.”
Bundy Group served as exclusive financial advisor in the transaction. Bundy Group was retained by Catawba Research based on the investment bank’s experience in the healthcare and life sciences sectors. Bundy Group managed a thorough process, which yielded significant buyer interest in the CRO and resulted in the Catawba Research shareholders achieving their financial and strategic goals. This successful transaction marks Bundy Group’s third healthcare transaction since April of this year.
About Catawba Research
Catawba Research is a vertically integrated contract research organization providing clinical management services to pharmaceutical and biotechnology companies globally. The Company focuses on Phase II – IV trials across the dermatology, women’s health, ophthalmology and gastroenterology therapeutic areas. Catawba Research manages clinical end point trials for New Drug Applications (NDA) and Abbreviated New Drug Applications (ANDA). The Company has established a global footprint with site relationships across the U.S., Central America and India. Since 2014, Catawba Research has engaged in nearly 50 clinical trials in 13 indications, achieving 15 agency approvals in the USA and Canada. The Company is headquartered in Charlotte, NC with additional locations in Texas, New Mexico and Michigan. The Company also provides data management, biostatistics, medical writing, and clinical CRO services through its location in Mumbai, India.
About Bundy Group
Bundy Group provides investment banking and transaction advisory services to clients across numerous markets, including healthcare and life sciences. The highly experienced team within Bundy Group includes transaction and operating professionals with a combined 100 years of experience in investment banking and corporate finance. As a 31-year-old boutique firm, the senior team leverages its specialized focus on our core markets to guide clients through the entire process of selling their company, raising capital, and pursuing acquisitions for growth.
